Clinical Trial Update: MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function [Phase 3]

View source ↗

Summary

A Phase 3 trial of MNK-6105 for hepatic encephalopathy in cirrhosis patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy

Drugs mentioned

• MNK-6105

Snippet

Sponsor: Mallinckrodt | Conditions: Hepatic Encephalopathy | Phase 3 | Status: WITHDRAWN